

CellaVision acquires exclusive rights to novel microscopy technology

CellaVision announces that the company has signed an agreement to acquire the exclusive rights to a patent portfolio on Fourier Ptychographic Microscopy, a novel microscopy technology from Clearbridge BioPhotonics. The acquisition gives CellaVision access and control of an interesting future technology. The acquisition has a cash purchase price of SEK 28,7 million.

The technology has been developed at California Institute of Technology and is a method for creating high-resolution images with low-magnification optics. This enables images of large areas to be acquired at high resolution with higher speed than using conventional digital microscopy.

CellaVision believes that the Fourier Ptychography Microscopy technology has potential to be used to develop future automated microscopes, with applications in both hematology and adjacent areas.

The acquisition is seen as a long-term investment aiming to strengthen CellaVision's innovation opportunities and will have no material impact on sales or EBITDA in the near-term future. The acquired patent rights provide protection in CellaVision's key geographies for more than 12 years.

Contact

Simon Østergaard
Chief Executive Officer
Mobil: +46 (0) 70 036 37 92
Direct: +46 (0) 46 460 16 23

Contact

Maria Morin
VP HR & Corporate Communications
Direct: +46 (0) 46 460 16 52
Mobile: +46 (0) 709 92 62 28

About Us

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company's 18 local market support organizations covering more than 40 countries. In 2020, sales were SEK 471 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-04-06 18:15 CEST.

Attachments

[CellaVision acquires exclusive rights to novel microscopy technology](#)